Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Study sponsor: Kyntra Bio
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-09-04Actual
Enrollment · participants372Actual
Source updated2024-08-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.